Oct 21 (Reuters) – Actinogen Medical Ltd: * NARROW GUIDANCE FOR TOPLINE RESULTS FOR XANAMIA PHASE 2B/3 ALZHEIMER'S DISEASE CLINICAL TRIAL TO MID-NOV THIS YEAR Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
BANGKOK, Oct 21 (Reuters) - The Thai baht was little changed against the US dollar…
London (dpa) - In what University of Cambridge scientists hope could lead to a "blueprint" for…
By Scott Murdoch and Rajasik Mukherjee SYDNEY Oct 21 (Reuters) - Australian data centre operator…
By Vibhuti Sharma and Aditya Kalra MUMBAI, Oct 21 (Reuters) - Public bidding for the…
Arseny Gritsyuk scored for the third straight game, Jake Allen made 18 of his 31…
HANOI, Oct 21 (Reuters) - Here is a snapshot of Vietnamese dong exchange rates in…